BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 34265774)

  • 1. Pressurized Intraperitoneal Aerosol Chemotherapy-Related Clinical Trials in the Treatment of Peritoneal Metastases.
    Ukegjini K; Putora PM; Guidi M; Süveg K; Cihoric N; Widmann B; Steffen T
    Oncology; 2021; 99(9):601-610. PubMed ID: 34265774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of life of patients with end-stage peritoneal metastasis treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC).
    Odendahl K; Solass W; Demtröder C; Giger-Pabst U; Zieren J; Tempfer C; Reymond MA
    Eur J Surg Oncol; 2015 Oct; 41(10):1379-85. PubMed ID: 26138283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC): A bidirectional approach for gastric cancer peritoneal metastasis.
    Di Giorgio A; Schena CA; El Halabieh MA; Abatini C; Vita E; Strippoli A; Inzani F; Rodolfino E; Romanò B; Pacelli F; Rotolo S
    Surg Oncol; 2020 Sep; 34():270-275. PubMed ID: 32891341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in combination with FOLFOX chemotherapy as a first-line treatment for gastric cancer patients with peritoneal metastases: single-arm phase II study.
    Luksta M; Bausys A; Bickaite K; Rackauskas R; Paskonis M; Luksaite-Lukste R; Ranceva A; Stulpinas R; Brasiuniene B; Baltruskeviciene E; Lachej N; Sabaliauskaite R; Bausys R; Tulyte S; Strupas K
    BMC Cancer; 2023 Oct; 23(1):1032. PubMed ID: 37875869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No Renal Toxicity After Repeated Treatment with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients with Unresectable Peritoneal Metastasis.
    Larbre V; Alyami M; Mercier F; Vantard N; Bonnefoy I; Opsomer MA; Villeneuve L; Bakrin N; Rioufol C; Glehen O; Kepenekian V
    Anticancer Res; 2018 Dec; 38(12):6869-6875. PubMed ID: 30504403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy: an innovative approach to treat peritoneal carcinomatosis.
    Robella M; Vaira M; De Simone M
    World J Surg Oncol; 2016 Apr; 14():128. PubMed ID: 27125996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) of peritoneal metastasis from gastric cancer: a descriptive cohort study.
    Ellebæk SB; Graversen M; Detlefsen S; Lundell L; Fristrup CW; Pfeiffer P; Mortensen MB
    Clin Exp Metastasis; 2020 Apr; 37(2):325-332. PubMed ID: 32002724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe hypersensitivity reactions to platinum compounds post-pressurized intraperitoneal aerosol chemotherapy (PIPAC): first literature report.
    Siebert M; Alyami M; Mercier F; Gallice C; Villeneuve L; Bérard F; Glehen O; Bakrin N; Kepenekian V
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):425-430. PubMed ID: 30511218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe peritoneal sclerosis after repeated pressurized intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC OX): report of two cases and literature survey.
    Graversen M; Detlefsen S; Pfeiffer P; Lundell L; Mortensen MB
    Clin Exp Metastasis; 2018 Mar; 35(3):103-108. PubMed ID: 29705882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter comprehensive methodological and technical analysis of 832 pressurized intraperitoneal aerosol chemotherapy (PIPAC) interventions performed in 349 patients for peritoneal carcinomatosis treatment: An international survey study.
    Nowacki M; Alyami M; Villeneuve L; Mercier F; Hubner M; Willaert W; Ceelen W; Reymond M; Pezet D; Arvieux C; Khomyakov V; Lay L; Gianni S; Zegarski W; Bakrin N; Glehen O
    Eur J Surg Oncol; 2018 Jul; 44(7):991-996. PubMed ID: 29526367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bidirectional treatment of peritoneal metastasis with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) and systemic chemotherapy: a systematic review.
    Ploug M; Graversen M; Pfeiffer P; Mortensen MB
    BMC Cancer; 2020 Feb; 20(1):105. PubMed ID: 32041558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients with gastric cancer and peritoneal metastasis.
    Javanbakht M; Mashayekhi A; Branagan-Harris M; Horvath P; Königsrainer A; Reymond MA; Yaghoubi M
    Eur J Surg Oncol; 2022 Jan; 48(1):188-196. PubMed ID: 34479745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastases of pancreas and biliary tract cancer.
    Horvath P; Beckert S; Struller F; Königsrainer A; Reymond MA
    Clin Exp Metastasis; 2018 Oct; 35(7):635-640. PubMed ID: 30062506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pressurized Intraperitoneal Aerosol Chemotherapy, a Palliative Treatment Approach for Patients With Peritoneal Carcinomatosis: Description of Method and Systematic Review of Literature.
    Winkler CS; Sandhu J; Pettke E; Merchea A; Fong Y; Kumara HMCS; Whelan RL
    Dis Colon Rectum; 2020 Feb; 63(2):242-255. PubMed ID: 31914116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis.
    Demtröder C; Solass W; Zieren J; Strumberg D; Giger-Pabst U; Reymond MA
    Colorectal Dis; 2016 Apr; 18(4):364-71. PubMed ID: 26400556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review of patient reported outcomes (PROs) and quality of life measures after pressurized intraperitoneal aerosol chemotherapy (PIPAC).
    Taibi A; Geyl S; Salle H; Salle L; Mathonnet M; Usseglio J; Durand Fontanier S
    Surg Oncol; 2020 Dec; 35():97-105. PubMed ID: 32862112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peritoneal metastasis from pancreatic cancer treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC).
    Graversen M; Detlefsen S; Bjerregaard JK; Pfeiffer P; Mortensen MB
    Clin Exp Metastasis; 2017 Jun; 34(5):309-314. PubMed ID: 28516306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nab-PIPAC: a phase IB study protocol of intraperitoneal cisplatin and nab-paclitaxel administered by pressurised intraperitoneal aerosol chemotherapy (PIPAC) in the treatment of advanced malignancies confined to the peritoneal cavity.
    Lang N; Diciola A; Labidi-Galy I; Ris F; Di Marco M; Mach N; Petignat P; Toso C; Undurraga M; Hubner M
    BMJ Open; 2023 Jan; 13(1):e067691. PubMed ID: 36604127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncological Outcomes After Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in the Treatment of Peritoneal Carcinomatosis.
    Tidadini F; Abba J; Quesada JL; Trilling B; Bonne A; Foote A; Faucheron JL; Arvieux C
    J Gastrointest Cancer; 2023 Jun; 54(2):632-641. PubMed ID: 35778645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PIPAC-OX: A Phase I Study of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy in Patients with Peritoneal Metastases.
    Kim G; Tan HL; Sundar R; Lieske B; Chee CE; Ho J; Shabbir A; Babak MV; Ang WH; Goh BC; Yong WP; Wang L; So JBY
    Clin Cancer Res; 2021 Apr; 27(7):1875-1881. PubMed ID: 33148667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.